Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...

The curious finding was revealed at the American Heart Association (AHA) annual congress in New Orleans over the weekend, and ...

CMS said the GENEROUS Model is aimed at "allowing Americans to benefit from fairer, more competitive pricing," adding that ...

Metsera said it expects the Pfizer deal to close promptly after a stockholder meeting scheduled for this coming Thursday ...

AstraZeneca highlighted blood pressure candidate baxdrostat as a programme to watch in its third-quarter results update, and new phase 3 data suggest that optimism is warranted. In the Bax24 study ...

The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 welcomes project leaders, procurement specialists and technical professionals from the whole value chain. On 20-21 April in ...

The merger of two pioneers of psychedelic medicines has completed with the creation of AtaiBeckley, a company with a pipeline ...

Shares in gene-editing specialist Intellia Therapeutics came under renewed pressure today after a patient in one of its ...

Pfizer – which first agreed a $4.9 billion takeover deal with Metsera in September – has argued that the rival bid is ...

The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...

Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the ...

Although rare kidney diseases remain a significantly overlooked contributor to the global burden of CKD, things have begun to ...